Drug Trial Radar · NCT06837896
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
111
Actual
Start
Mar 11, 2025
Primary completion
Jan 15, 2026
Study completion Jan 15, 2026
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.
Conditions
- Prostate Cancer
Interventions
QLG1080Drug
Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sustained castration rate of serum testosteroneTime frame: From study day 29 to the end of the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
No. 8888 Lvyou Road
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.